Abstract：Objective To investigate the efficacy of initial antiviral treatment in patients with human immunodeficiency virus (HIV) infection/acquired immunodeficiency syndrome (AIDS) in Qinhuangdao from 2019 to 2021, and to provide a reference basis for further improving HIV/AIDS antiviral treatment in Qinhuangdao. Methods We recruited the baseline data about HIV-infected persons/AIDS patients aged 18 years and above who received antiviral treatment for HIV/AIDS and the related data after 6 months of antiviral treatment in Qinhuangdao during 2019-2021, and then analyzed the effect of antiviral therapy. Results After 6 months of antiviral treatment, 24 out of 450 HIV/AIDS patients had virological suppression failure, with the virological suppression failure rate being 5.33%. The results of multi-factor analysis revealed that the middle-aged population (OR=1.269, 95%CI: 1.025-1.571) and the elderly population (OR=1.645, 95%CI:1.165-2.323) had a higher risk of virological suppression failure (P=0.029) after 6 months of antiviral treatment than the young population. Compared with the time interval between diagnosis and treatment of < 6 months, the risk of virological suppression failure in the time interval between diagnosis and treatment of ≥ 6 months (OR=1.650, 95%CI:1.142-2.386) was higher (P=0.008). Patients with baseline CD+4 T lymphocyte counts 350-499 cells/μl (OR=0.752, 95%CI:0.632-0.895) and > 500 cells/μl (OR=0.672, 95%CI: 0.534-0.845) had a lower risk of virological suppression failure than those with baselineCD+4 T lymphocyte count <200 cells/μl. Patients with clinical stages III-IV (OR=1.594, 95%CI:1.267-2.004), other treatment regimens (OR=1.422, 95%CI: 1.058-1.912), missed medication (OR=1.487, 95%CI: 1.194-1.852) and adverse drug reactions (OR=1.507, 95%CI: 1.186-1.914) had a higher risk of virological suppression failure.Conclusion There are still some HIV/AIDS patients who fail to achieve virus suppression in antiviral therapy forHIV/AIDS offered free in Qinhuangdao. Special attention should be paid to the therapeutic effect among the middle-aged and elderly populations with HIV/AIDS. In addition, early detection, early diagnosis, early treatment and promoting patients'compliance are crucial for improving the effect of antiviral therapy. Antiviral treatment has been affected by theSARS-CoV-2 pandemic in the last two years, thus leading to some patients being unable to get and take the medicine on time.
[1] 揣征然, 张云辉, 赵雅琳, 等. 全球及中国AIDS最新疫情概况[J]. 传染病信息, 2020, 33(6):501-503. [2] Griffen AL,Thompson ZA,Beall CJ,et al. Significant effect of HIV/HAART on oral microbiota using multivariate analysis[J]. Sci Rep, 2019, 9(1):19946. [3] 李太生. 如何提高我国抗艾滋病病毒治疗成功率[J]. 中华医学杂志, 2011,97(21):1441-1442. [4] 中国艾滋病诊疗指南(2018版)[J]. 传染病信息, 2018, 31(6):481-499,504. [5] Politocs PL. Antiretrovirol therapy for HIV infection in adults and adolescents: recommendation for a public health approach. 2006 revision[R].Geneva: WHO,206:1-132. [6] 唐建梅, 陆红达, 徐银, 等. 江阴市HIV/AIDS患者首次接受抗病毒治疗效果分析[J]. 公共卫生与预防医学, 2022, 33(3):109-112. [7] 段振华, 范双凤, 吴学庆, 等. 成都市2008—2018年艾滋病抗病毒治疗病毒学失败影响因素[J]. 中国公共卫生, 2020, 36(8):1237-1241. [8] 李超锋, 杨萱, 杨晓霞, 等. 郑州市HIV/AIDS病人一线抗病毒治疗失败发生规律及影响因素分析[J]. 中国艾滋病性病, 2019, 25(3):239-242. [9] 覃彤雪, 邓本本, 徐月香, 等. 2007—2020年贵港市HIV/AIDS初治患者抗病毒治疗效果及相关因素分析[J]. 广西医科大学学报, 2022, 39(12):1876-1882. [10] 张玉鹏,杨斌,肖俊,等. 黔东南州HIV感染者抗病毒治疗后病毒载量结果分析[J]. 微量元素与健康研究,2020,37(1):45-46. [11] 王永勤, 赵静, 尹志红,等. 2012—2017年潍坊市艾滋病抗病毒治疗失败影响因素分析[J]. 传染病信息, 2021, 34(3):254-257. [12] 曹咏红, 张勇, 谭毅. 影响艾滋病抗病毒治疗效果有关因素的研究进展[J]. 中国临床新医学, 2013,6(8):822-825. [13] 谢莹,安文红,赵地, 等. 参加社区健康体检的50岁及以上人群艾滋病相关知识、性行为及HIV检测的接受度调查[J].实用预防医学,2022,29(12):1414-1418. [14] 朱晓艳, 黄涛, 王国永, 等. 山东省50岁及以上HIV感染者和艾滋病患者抗病毒治疗效果分析[J]. 中华疾病控制杂志, 2016, 20(12):1199-1202,1207. [15] 张曼华, 徐勤, 张辉, 等. 艾滋病相关老年人群心理健康状况调查[J]. 中国公共卫生, 2007, 23(9):1069-1070. [16] Supervie V,Marty L,Lacombe JM,et al. Looking beyond the cascade of HIV care to end the AIDS epidemic: estimation of the time interval from HIV infection to viral suppression[J]. J Acquir Immune Defic Syndr, 2016, 73(3):348-355. [17] 杜云玲, 万钢, 吴焱, 等. HIV/AIDS病人HAART后免疫重建相关影响因素分析[J]. 中国艾滋病性病, 2015, 21(6):470-473,500. [18] 张可, 董培玲, 强来英, 等. 160例成人HIV感染者/AIDS患者机会性感染与CD+4之间关系分析[J]. 中国艾滋病性病, 2003, 9(1):5-7. [19] Fentie Wendie T,Workneh BD. Prevalence and predictors of virological failure among adults living with HIV in South Wollo Zone, northeast Ethiopia: a retrospective cohort study[J]. HIV AIDS (Auckl), 2020, 12:393-402. [20] 周涛, 李月飞, 白雪, 等. 伊犁州吸毒人群中HIV/AIDS患者抗病毒治疗效果及其影响因素分析[J]. 中国艾滋病性病, 2021, 27(4):352-355. [21] Spaulding A, Rutherford GW, Siegfried N. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naive individuals[J]. Cochrane Database Syst Rev,2010,10:CD008740. [22] Chendi BH, Okomo Assoumou MC, Jacobs GB, et al. Rate of viral load change and adherence of HIV adult patients treated with efavirenz or nevirapine antiretroviral regimens at 24 and 48 weeks in Yaounde, Cameroon: a longitudinal cohort study[J]. BMC Infect Dis, 2019, 19(1):194. [23] Howard AA,Arnsten JH,Lo Y,et al. A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women[J]. AIDS, 2002, 16(16):2175-2182.
2023, Vol. 30 
